Via International Federation of Pharmaceutical Manufacturers & Associations, a pdf document, excerpt :
" The 2009-10 H1N1 influenza pandemic prompted the most robust and complete pandemic response ever. As with any major public health initiative of this scale, it is important that stakeholders undertake a careful analysis of the response. This will help enhance future preparedness, by building on those areas that were successful, and improving those that were less so.
From the perspective of the vaccine manufacturers, several elements of the response were particularly effective:
High level of preparedness. For many years prior to the H1N1 outbreak, public health authorities, regulatory agencies and vaccine producers worked together on pandemic preparedness. These efforts intensified following the spread of H5N1 'avian' influenza. The resulting level of preparedness allowed authorities to respond robustly to the H1N1 pandemic, in a manner that was not previously possible."